We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GC Medical Science corp.

Download Mobile App





Researchers Find Untapped Potential for AI-Enhanced Chest X-Ray Imaging in COVID-19 Diagnosis

By HospiMedica International staff writers
Posted on 08 Jun 2020
Researchers have suggested that artificial intelligence (AI) should be used to expand the role of chest X-ray imaging — using computed tomography (CT) — in diagnosing and assessing coronavirus infection so that it can be more than just a means of screening for signs of COVID-19 in a patient’s lungs. More...


Although CT chest imaging is not currently a routine method for diagnosing COVID-19 in patients, it has been helpful in excluding other possible causes for COVID-like symptoms, confirming a diagnosis made by another means or providing critical data for monitoring a patient’s progress in severe cases of the disease. However, based on their study, researchers at the John Hopkins University (Baltimore, MD, USA) believe that this isn’t enough, making the case that there is “an untapped potential” for AI-enhanced imaging to improve. According to the researchers, “AI’s power to generate models from large volumes of information — fusing molecular, clinical, epidemiological and imaging data — may accelerate solutions to detect, contain and treat COVID-19.”

The Johns Hopkins Medicine researchers have suggested that AI can be used for risk stratification, the process of categorizing patients for the type of care they receive based on the predicted course of their COVID-19 infection. The technology can also be used for treatment monitoring to define the effectiveness of agents used to combat the disease, as well as for modeling how COVID-19 behaves, so that novel, customized therapies can be developed, tested and deployed. The researchers have proposed that “AI may help identify the immunological markers most associated with poor clinical course, which may yield new targets” for drugs that will direct the immune system against the SARS-CoV-2 virus that causes COVID-19.

Related Links:
Johns Hopkins University


Platinum Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Disposable Protective Suit For Medical Use
Disposable Protective Suit For Medical Use
Cardiograph Device
PageWriter TC35
Morcellator
TCM 3000 BL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: Professor Bumsoo Han and postdoctoral researcher Sae Rome Choi of Illinois co-authored a study on using DNA origami to enhance imaging of dense pancreatic tissue (Photo courtesy of Fred Zwicky/University of Illinois Urbana-Champaign)

DNA Origami Improves Imaging of Dense Pancreatic Tissue for Cancer Detection and Treatment

One of the challenges of fighting pancreatic cancer is finding ways to penetrate the organ’s dense tissue to define the margins between malignant and normal tissue. Now, a new study uses DNA origami structures... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.